看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -1.4x - -1.5x | -1.4x |
| Historical Pb Multiple | -2.8x - 7.8x | -2.3x |
| Fair Value | $5.44 - $6.01 | $5.72 |
| Upside | -40.6% - -34.3% | -37.5% |
| Benchmarks | - | Full Ticker |
| Teva Pharmaceutical Industries Limited | - | OTCPK:TEVJ.F |
| Merck & Co., Inc. | - | NYSE:MRK |
| AstraZeneca PLC | - | NasdaqGS:AZN |
| Regeneron Pharmaceuticals, Inc. | - | NasdaqGS:REGN |
| Harmony Biosciences Holdings, Inc. | - | NasdaqGM:HRMY |
| OptiNose, Inc. | - | NasdaqGS:OPTN |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| TEVJ.F | MRK | AZN | REGN | HRMY | OPTN | |||
| OTCPK:TEVJ.F | NYSE:MRK | NasdaqGS:AZN | NasdaqGS:REGN | NasdaqGM:HRMY | NasdaqGS:OPTN | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | 24.6% | 39.4% | 15.8% | NM- | NM- | ||
| 3Y CAGR | NM- | 11.5% | 297.5% | -18.2% | 61.4% | NM- | ||
| Latest Twelve Months | -193.2% | 4589.6% | 18.1% | 11.6% | 12.9% | 39.3% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -10.5% | 18.8% | 8.8% | 38.3% | -20.1% | -119.7% | ||
| Prior Fiscal Year | -3.5% | 0.6% | 13.0% | 30.1% | 22.1% | -50.0% | ||
| Latest Fiscal Year | -9.9% | 26.7% | 13.0% | 31.1% | 20.4% | -27.5% | ||
| Latest Twelve Months | -9.9% | 26.7% | 13.0% | 31.1% | 20.4% | -27.5% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -16.3% | 26.0% | 13.7% | 28.6% | 14.7% | -768.0% | ||
| Prior Fiscal Year | -7.3% | 0.9% | 15.6% | 16.3% | 29.6% | NM | ||
| Latest Twelve Months | -25.5% | 40.8% | 17.6% | 16.0% | 25.8% | NM | ||
| Next Fiscal Year | 43.2% | 42.8% | 30.5% | 16.5% | 30.3% | 26.1% | ||
| Two Fiscal Years Forward | 31.8% | 36.7% | 28.6% | 16.5% | 29.3% | 59.0% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 1.1x | 3.4x | 4.1x | 4.6x | 2.6x | 1.2x | ||
| Price / LTM EPS | -10.7x | 12.9x | 31.8x | 15.0x | 12.8x | -4.3x | ||
| Price / Book | 3.3x | 4.8x | 5.5x | 2.2x | 2.8x | -2.3x | ||
| Price / Fwd Book | 2.0x | 3.7x | 4.5x | 2.2x | 2.1x | -1.8x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 2.2x | 3.3x | 5.5x | |||||
| Historical P/B Ratio | -2.8x | -2.3x | 7.8x | |||||
| Selected P/B Multiple | -1.4x | -1.4x | -1.5x | |||||
| (x) Book Value | (40) | (40) | (40) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | TEVJ.F | MRK | AZN | REGN | HRMY | OPTN | |
| Value of Common Equity | 16,958 | 220,068 | 223,862 | 66,034 | 1,859 | 92 | |
| (/) Shares Outstanding | 1,145.8 | 2,526.0 | 3,083.5 | 107.0 | 57.3 | 10.1 | |
| Implied Stock Price | 14.80 | 87.12 | 72.60 | 617.00 | 32.42 | 9.15 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 14.80 | 87.12 | 72.60 | 617.00 | 32.42 | 9.15 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |